Irritable Bowel Syndrome (IBS) Treatment Market Share, Size, and Outlook by 2028
Irritable Bowel Syndrome (IBS) Treatment Market: Strategic Insights
Irritable Bowel Syndrome (IBS) Treatment Market
-
CAGR (2020 - 2028)10.1% -
Market Size 2020
US$ 2.15 Billion -
Market Size 2028
US$ 4.6 Billion
Market Dynamics
GROWTH DRIVERS
- Rising prevalence of IBS
- Advances in drug development
- Commercialization of established therapies
- Aging Population
- Rising Healthcare Expenditure
- Personalized Medicine
- Rising Interest in Probiotics and Dietary Supplements
- Telehealth and Digital Health Solutions
- Emerging Markets with a Growing Middle Class
FUTURE TRENDS
- Precision Medicine
- Gut Microbiome Research
- AI and ML
- Digital Health and Telemedicine
- Functional Foods and Nutraceuticals
- Combination Therapies
- Patient Centered Care
- Global Collaboration
OPPORTUNITIES
- New Drugs and Treatments for IBS Subtypes
- Personalized Medicine
- Probiotics and Dietary Supplements
- Digital Health Solutions
- Combination Therapies
- OTC Products
- Functional Foods and Nutraceuticals
Key Players
- Ironwood Pharmaceuticals Inc
- AbbVie
- Sebela Pharmaceuticals Inc
- Takeda Pharmaceutical Company Limited
- Alfasigma S p A
- Astellas Pharma Inc
- AstraZeneca
- Synthetic Biologics Inc
- Bausch Lomb Incorporated
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
Type - IBS with Diarrhea
- IBS with Constipation
- Mixed IBS
Product - Rifaximin
- Eluxadoline
- Lubiprostone
- Linaclotide
Distribution Channel - Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Pharmacies
Get Free Sample For